全国性研究中质子泵抑制剂的使用与髋部骨折后死亡率的关系
该回顾性队列研究分析奥地利31668例≥50岁髋部骨折患者,比较未用抗骨质疏松药物者中骨折前或骨折后首次处方质子泵抑制剂(PPI)与两者均未使用者的全因死亡率。结果显示骨折前启用PPI者90天死亡率降低但半年后死亡率升高;住院期间启用PPI者院内死亡率0.2%低于匹配对照3.5%,出院后启用PPI者90天死亡率降低(<70岁患者除外)。
要点
- 骨折前或骨折后启用PPI均与90天死亡率显著降低相关(OR分别为0.66和0.23)。
- 住院期间开始PPI者院内死亡率0.2%,显著低于匹配对照的3.5%。
- 骨折前启用PPI者骨折半年后远期死亡率显著升高。
核心结论
- 髋部骨折住院期间及出院后使用PPI与死亡率大幅降低相关,这些发现可能对髋部骨折治疗有启示。
研究设计与样本
- 回顾性队列研究,纳入2008年7月至2010年12月奥地利31668例≥50岁髋部骨折患者,PPI使用数据来自全国数据库。
- 比较未用抗骨质疏松药物者中骨折前或骨折后首次记录PPI处方者与既未用PPI也未用抗骨质疏松药物者的全因死亡率,采用logistic回归和Cox回归分析。
主要发现
- 骨折前启用PPI者90天死亡率OR 0.66(p<0.0001),骨折后启用PPI者90天死亡率OR 0.23(p<0.0001)。
- 直至末次髋部骨折相关住院出院后才处方PPI者90天死亡率降低(OR 0.49;p<0.0001),但<70岁患者除外。
- 住院期间开始PPI的亚组院内死亡率为0.2%,匹配对照患者为3.5%(p<0.0001),相对大幅降低。
- 仅骨折前开始PPI处方者骨折半年后远期死亡率显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We analyzed the association of proton pump inhibitors (PPIs) with mortality after osteoporosis-related hip fracture in Austria. PPIs were associated with reduced 90-day mortality but elevated mortality after half a year when initiated pre-fracture. Inpatients and discharged patients on PPIs showed lowered in-hospital and 90-day mortality, respectively. INTRODUCTION: We herein investigated use of proton pump inhibitors (PPIs) and mortality among hip fracture patients in a nationwide study in Austria. METHODS: In this retrospective cohort study, data on use of PPIs were obtained from 31,668 Austrian patients ≥50 years with a hip fracture between July 2008 and December 2010. All-cause mortality in patients without anti-osteoporotic drug treatment who had received their first recorded PPI prescription in the study period either before or after fracture was compared with hip fracture patients on neither PPIs nor anti-osteoporotic medication using logistic and Cox regression analysis. RESULTS: With PPI use, 90-day mortality was significantly reduced, both at initiation before (OR 0.66; p < 0.0001) and after hip fracture (OR 0.23; p < 0.0001). 90-day mortality was also reduced when PPIs were prescribed not until after discharge from the last recorded hip fracture-related hospital stay (OR 0.49; p < 0.0001) except for patients aged <70 years. In a sub-cohort of patients beginning PPIs during hospital stay, in-hospital mortality (0.2%) was substantially reduced relative to matched control patients (3.5%) (p < 0.0001). Longer-term mortality significantly increased after half a year post-fracture only among those who started PPI prescription before fracture. CONCLUSIONS: PPI use during and after hospital stay due to hip fracture is associated with a considerable decrease in mortality. These findings could have implications for hip fracture treatment.
引用
- Brozek W, Reichardt B, Zwerina J, et al. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos Int. 2017. PMID: 28083667. doi:10.1007/s00198-017-3910-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。